Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

portrait

portrait

Pramila Rijal

DPhil

RDM Principal Investigator

  • COI Career Development Fellow/ Group Leader

Antibodies, Vaccine and Drug against Influenza virus

Antibodies and Vaccine Development Against Infectious Viruses

Dr. Pramila Rijal is a researcher focused on infectious diseases, particularly Influenza and Ebola viruses. She received her Ph.D. from the University of Oxford in 2017, where she studied the human monoclonal antibody response to these viruses after natural infection and vaccination. With over ten years of research experience, Dr. Rijal has developed expertise in antibody and vaccine development. Her current work centres on the influenza neuraminidase (NA) protein, which is crucial for developing effective treatments and vaccines.

Research Focus

Dr. Rijal's research includes:

  1. Monoclonal Antibodies: Characterising the protective antibodies targeting NA protein
  2. Vaccine Development: Engineering the NA protein and developing NA-based nanoparticle vaccines with the aim of generating a broader and higher-quality antibody response
  3. Drug Discovery: Identifying new drugs that target the neuraminidase protein to advance antiviral therapies.

The funding support comes from the CAMS-Oxford Institute and the Novo-Nordisk Foundation. 

https://www.rdm.ox.ac.uk/research/rijal-group

https://www.camsoxford.ox.ac.uk/research/groups/rijal-group